[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
Octave Bioscience scores $30M for neurodegenerative disease offerings
The multiple sclerosis-focused company will use the funds to speed up the company ' s commercialization efforts. (Source: mobihealthnews)
Source: mobihealthnews - July 26, 2023 Category: Information Technology Source Type: news
The Earlier MS Is Treated, the Better
WEDNESDAY, July 26, 2023 -- Patients who get treatment for multiple sclerosis at the earliest signs of disease may have a lower risk of disability later, new research suggests.
Among nearly 600 patients, there were lower odds of disability and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 26, 2023 Category: General Medicine Source Type: news
Biogen to Cut Roughly 11% of Workforce to Focus on Big-Return Drugs
Biogen has seen revenue decline in recent years partly owing to increased competition for its multiple-sclerosis drugs. Biogen said it is eliminating about 1,000 jobs, or about 11% of its workforce, after the drugmaker’s new chief executive concluded it had too many costly drug-research projects…#biogen (Source: Reuters: Health)
Source: Reuters: Health - July 25, 2023 Category: Consumer Health News Source Type: news
Starting with Human Cell Systems
Xitiz Chamling shares how advances in human stem cell and gene editing technologies fuel his drive for better multiple sclerosis drug screening platforms. (Source: The Scientist)
Source: The Scientist - July 24, 2023 Category: Science Tags: Podcasts Source Type: news
CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Media News - July 21, 2023 Category: Pharmaceuticals Source Type: news
CHMP recommends Roche ’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)
Positive recommendation is based on interim data from ongoing RAINBOWFISH trial which showed majority ofEvrysdi-treated babies were able to stand and walk within timeframes typical of healthy babies by 12 months ’ treatment1,2If approved by the European Commission,Evrysdi will be available to treat people of all ages with SMA in the European Union, including babies from birthEvrysdi is now approved in 100 countries with more than 8,500 patients treated globallyBasel, 21 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive o...
Source: Roche Investor Update - July 21, 2023 Category: Pharmaceuticals Source Type: news
Early MS Treatment Tied to a Reduction in Severe Disability Early MS Treatment Tied to a Reduction in Severe Disability
Initiating treatment within 6 months of the first symptoms of multiple sclerosis is linked to a 45% lower risk for disability years later.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 20, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Early Treatment of Demyelination Events Cuts Long-Term Disability in MS
THURSDAY, July 20, 2023 -- For multiple sclerosis patients with a first demyelinating event, earlier treatment initiation is associated with a reduction in the risk for long-term disability, according to a study published online July 19 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2023 Category: Pharmaceuticals Source Type: news
Comparison of physical performance, gait, balance, falls efficacy, and step reaction time in individuals with multiple sclerosis - Özden F, Özkeskin M, Tümtürk, Yüceyar N.
OBJECTIVE: The study aimed to investigate the physical performance, gait, balance, falls efficacy, and step reaction time in individuals with MS. METHODS: A total of 60 individuals (30 individuals with MS and 30 age and sex-matched healthy controls... (Source: SafetyLit)
Source: SafetyLit - July 19, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Searching for a Direct Route to Multiple Sclerosis Treatment
Researchers created a new high-throughput tool to hunt for therapies that remyelinate the nervous system. (Source: The Scientist)
Source: The Scientist - July 17, 2023 Category: Science Tags: News News & Opinion Source Type: news
Retinal Thickness a New Predictor of MS Disability? Retinal Thickness a New Predictor of MS Disability?
Measuring the thickness of the retina shortly after diagnosis in multiple sclerosis patients could predict their risk of accumulated disability later in the disease course, say Austrian researchers.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 14, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Interferon Tumbles, Oral Agents Gain as Initial MS Treatment
(MedPage Today) -- Prescribing patterns of initial disease-modifying therapies for multiple sclerosis have shifted dramatically since 2001, with oral agents driving down the use of platform injectables 73.8% by 2020.
The inflection point occurred... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - July 13, 2023 Category: Neurology Source Type: news
What To Know About Djokovic ’s Nano Patch And Why Some Experts Call It ‘Pseudoscience’
The patch is called a TaoPatch and is produced by an Italian company that claims the device can boost athletic performance, improve diseases like multiple sclerosis and build stamina. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 13, 2023 Category: Pharmaceuticals Authors: Arianna Johnson, Forbes Staff Tags: Innovation /innovation Science /science Healthcare /healthcare Breaking breaking-news Trending Explainer Trending-Explainer topline Source Type: news
